.png)
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders.
Cyprotex (www.cyprotex.com), an Evotec company since 2016, was founded in 1999 and specialises in in vitro and in silico ADME-Tox. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during preclinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and modelling and simulation expertise.
Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.
Evotec operates globally with more than 4,200 highly qualified people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.
For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.